Fundraising FoxSamsara BioCapital — 2018 Investments
3 investments dated 2018 · listed companies and verified rows first · show all
Sutro is a biotech company developing a cell-free protein synthesis platform for the design and manufacturing of complex biologics, particularly cancer therapies and antibody-drug conjugates.
BiotechDeep TechHealthtechMedical DevicesSouth San Francisco, US
William J. Newell(Executive Officer, Director)Jane Chung(Chief Executive Officer)inHans-Peter Gerber(Chief Scientific Officer)inDavid Pauling(Chief Administrative Officer and General Counsel)inJonathan Fawcett(VP, Head of Clinical Development)inDevendra Luhar(SVP, Technical Operations)in
Board seatMichael Bryan Dybbs· per SEC Form D
Co-investorsOwl CapitalRidgeback CapitalSolasta VenturesSV Health InvestorsVida Ventures
Biotechnology company developing products for overactive bladder and irritable bowel syndrome.
BiotechMalvern, US
Douglas Gessl(Executive Officer)inJames Walker(Executive Officer, Director)in
BoardScott Morenstein(Director)David Hirsch(Director)James Bennethum(Director)Stephen Tullman(Director)
Co-investorsFountain Healthcare PartnersLongitude Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.